Roche Warns of “Tectonic Shifts” as Switzerland Loses Ground in Global Pharma Race
Table of Contents
Switzerland’s pharmaceutical industry is facing increasing pressure from global competition and protectionist policies, prompting Roche’s leadership to warn of important challenges ahead. The shifting landscape threatens to diminish Switzerland’s attractiveness as a key investment location, despite ongoing commitments like Roche’s new $560 million research and advancement center in Basel.
Roche Chairman of the Board of Directors, Severin schwan, recently c
The primary driver of this uncertainty is the increasingly assertive trade policy of the United States. According to reports, the US President is threatening significant tariffs aimed at incentivizing pharmaceutical companies – including Roche and Novartis – to increase domestic production while simultaneously attempting to lower record-high drug prices.Companies failing to commit to price reductions or increased US investment face the prospect of punitive tariffs.
This pressure is compounded by the rising competitiveness of other European nations.Denmark, Sweden, and the Netherlands are actively courting pharmaceutical investment, creating a more challenging environment for Switzerland.”Due to increasing protectionism in our core markets, we are forced to relocate,” Schwan stated, adding that this reallocation of investment inevitably reduces the funds available for locations like basel and the wider Swiss economy.
Switzerland’s Declining Competitiveness
These shifts are already reflected in recent industry rankings. Switzerland has fallen from second to third place in the competitive rankings compiled by the Scienceindustries association, while the United States maintains its leading position and Ireland has moved into second.The rankings consider factors such as value creation, innovative strength, and overall location quality.
The Most Competitive Pharmaceutical Locations:
- USA
- Ireland
- Switzerland
- Denmark
- Netherlands
- United Kingdom
- Belgium
- South Korea
- Sweden
- Japan
Despite retaining a strong position in terms of framework conditions – including political stability, infrastructure, and taxation, where it ranks first globally – Switzerland is lagging in innovation. A five-year comparison reveals a “gradual deterioration” in the country’s overall competitiveness, according to Michael Grass, author of the study from BAK Economics.
European nations are aggressively pursuing pharmaceutical investment through substantial incentives.France, such as, has launched the “innovation Santé 2030” program, allocating €9 billion – six times the current budget of ETH Zurich – to foster a thriving biotech sector. Similar initiatives are underway in China, Germany, and the United Kingdom.
Industry leaders acknowledge the need for a strategic response, but remain hesitant about direct government intervention. Annette Luther, President of Scienceindustries, stated that Switzerland has historically benefited from a hands-off approach to funding. “The more money the state talks about, the more likely it is to intervene. We want to maintain our independence.”
However, Luther conceded that proactive measures are necessary to ensure switzerland remains a top location for pharmaceutical investment. These include strengthening ties with the European union, offering tax incentives for research, implementing a flexible approach to the OECD minimum tax, and bolstering higher education. A location strategy for the pharmaceutical sector is currently under consideration by parliament.
Recent discussions between industry representatives and Federal Councilors guy parmelin and Elisabeth Baume-Schneider signal a growing awareness within the government of the challenges facing the sector.
While Luther cautioned against “alarmism,” acknowledging that companies have anticipated the trend toward localized production, she emphasized that the “tectonic shifts” will likely have long-term consequences. She pointed to the industry’s strong growth in Switzerland in recent years, suggesting that stagnation or minor reductions in investment may be less instantly noticeable.
Ultimately, the future of Switzerland’s pharmaceutical industry hinges on the response of policymakers. As Schwan underscored from 20 meters below ground, “We have to become more productive.”
